Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
1994-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of treatment with epoetin alfa versus
placebo on the percentage of red blood cells in anemic patients with chronic lymphocytic
(white blood cell) leukemia and its effect on the patients' quality-of-life. Epoetin alfa is
a genetically engineered protein that stimulates red blood cell production.
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.